3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Methylprednisolone
4
Flow Cytometry
4
Psychiatric Rehabilitation
3
Early Intervention, Educational
3
Antilymphocyte Serum
3
Radiotherapy
2
Melphalan
2
Immunologic Techniques
2
Cyclophosphamide
2
Busulfan
2
Azacitidine
2
Alemtuzumab
2
thymoglobulin
1
sargramostim
1
ruxolitinib
1
rucaparib
1
fludarabine phosphate
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
bemcentinib
1
aldesleukin
1
abiraterone
1
Zoledronic Acid
1
Voriconazole
1
Therapeutics
1
Tacrolimus
1
Stem Cell Transplantation
1
Rituximab
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
bemcentinib
×
CNS
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts